Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to comp ...

Gain insights, see trends and get real-time updates when you securely link or manually add your brokerage accounts.